200734 A New Trade Agreement on Pharmaceutical Pricing and Reimbursement?

Tuesday, November 10, 2009: 3:10 PM

Sharon Treat , National Legislative Association on Prescription Drug Prices, Hallowell, ME
Evidence-based drug pricing strategies employed by health officials in other countries have come under attack from US trade officials acting on behalf of the branded pharmaceutical industry. Trade policy now seeks to influence formulary listing decisions based on the comparison of new medicines to existing ones. The federal government's goals include implementing rules that favor patented products over generic ones, and that give industry greater input in listing decisions. Trade officials have used Free Trade Agreement negotiations and less formal bilateral consultations to advance these goals. Last year, Pfizer proposed a multilateral trade agreement among developed countries to ‘set disciplines' on ‘pricing and reimbursement policies.' Such a trade agreement could harm programs that serve the poor in the United States and use the same type of evidence based pricing strategies to negotiate discounts. State leaders fear this drive to set international norms for evidence-based drug pricing that favor the branded drug industry will undermine the ability to negotiate discounts for Medicaid – which serves 58 million low income Americans.

Learning Objectives:
Explain Pfizer-backed initiative for a trade agreement on pharmaceutical pricing and reimbursement policies. Evaluate its potential effect on US state government programs that negotiate drug prices.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: State Senator from Maine. Executive Director of NLARx, a group of other state legislators concerned with pharmaceutical prices.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.